Mechanism of diabetic neuropathy: Where are we now and where to go?

Journal of Diabetes Investigation

Volumn 2, Issue 1, 2011, Pages 18-32

  Yagihashi, Soroku ^a   Mizukami, Hiroki ^a   Sugimoto, Kazuhiro ^b  

^a HIROSAKI UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

Diabetic neuropathy; Novel treatment; Pathogenesis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; BENFOTIAMINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; CYCLOOXYGENASE 2; CYTOKINE; EPALRESTAT; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE; NEUROTROPHIN; NEUROTROPHIN 3; POLYOL; PROTEIN KINASE C; RUBOXISTAURIN; THIOCTIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANATOMICAL CONCEPTS; AUTOREGULATION; BONE MARROW CELL; CYTOKINE RELEASE; DIABETIC NEUROPATHY; DISEASE COURSE; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; GLYCATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NERVE FIBER DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PERIPHERAL NERVE INJURY; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 79960525595     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2010.00070.x     Document Type: Review

References (164)

1. Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962.
2. Strotmeyer ES, de Rekeneire N, Schwartz AV, et al. Sensory and motor peripheral nerve function and lower-extremity quadriceps strength: the health, aging and body composition study. J Am Geriatr Soc 2009; 57: 2004-2010.
3. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed. Diabetes Care 1978; 1: 168-188.
4. Vinik AI, Liuzze FJ, Holland MT, et al. Diabetic neuropathies. Diabetes Care 1992; 15: 1926-1975.
5. Ewing DJ, Campbell IW, Clarke BF. Mortality in diabetic autonomic neuropathy. Lancet 1976; 1: 601-603.
6. Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. Q J Med 1980; 49: 95-108.
7. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007; 115: 387-397.
8. Sabanayagam C, Liew G, Tai ES, et al. Relationship between glycated haemoglobin and microvascular complications: is there a natural cut-off point for the diagnosis of diabetes? Diabetologia 2009; 52: 1279-1289.
9. Pop-Busui R, Lu J, Lopes N, et al. Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. J Peripher Nerv Syst 2009; 14: 1-13.
10. Diabetes Control and Complications Trial Research Group: the effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
11. Martin CL, Albers J, Herman WH, et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006; 29: 340-344.
12. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
13. UK ProspectiveDiabetesStudyGroup. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 1998; 352: 837-853.
14. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341-350.
15. Vincent AM, Hinder LM, Pop-Busui R, et al. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst 2009; 14: 257-267.
16. Yagihashi S, Yasuda H, Deguchi T, et al. Clinical staging of diabetic polyneuropathy and its risk factors for the severity. 20th Neurodiab Meeting, Stockholm, Sept 17-20, 2010
17. Kihara M, Weerasuriya A, Low PA. Endoneurial blood flow in rat sciatic nerve during development. J Physiol 1991; 439: 351-360.
18. Sugimoto H, Monafo WW. Regional blood flow in sciatic nerve, biceps femoris muscle, and truncal skin in response to hemorrhagic hypotension. J Trauma 1987; 27: 1025-1030.
19. Smith DR, Kobrine AI, Rizzoli HV. Absence of autoregulation in peripheral nerve blood flow. J Neurol Sci 1977; 33: 347-352.
20. Sima AA, Nathaniel V, Prashar A, et al. Endoneurial microvessels in human diabetic neuropathy. Endothelial cell dysjunction and lack of treatment effect by aldose reductase inhibitor. Diabetes 1991; 40: 1090-1099.
21. Grover-Johnson NM, Baumann FG, Imparato AM, et al. Abnormal innervation of lower limb epineurial arterioles in human diabetes. Diabetologia 1981; 20: 31-38.
22. Beggs J, Johnson PC, Olafsen A, et al. Innervation of the vasa nervorum: changes in human diabetics. J Neuropathol Exp Neurol 1992; 51: 612-629.
23. Yagihashi S, Matsunaga M. Ultrastructural pathology of peripheral nerves in patients with diabetic neuropathy. Tohoku J Exp Med 1979; 129: 357-366.
24. Dyck PJ, Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review. J Neuropathol Exp Neurol 1996; 55: 1181-1193.
25. Dyck PJ, Karnes J, O'Brien P, et al. Spatial pattern of nerve fiber abnormality indicative of pathologic mechanism. Am J Pathol 1984; 117: 225-238.
26. Dyck PJ, Karnes JL, O'Brien P, et al. The spatial distribution of fiber loss in diabetic polyneuropathy suggests ischemia. Ann Neurol 1986; 19: 440-449.
27. Llewelyn JG, Thomas PK, Gilbey SG, et al. Pattern of myelinated fibre loss in the sural nerve in neuropathy related to type 1 (insulin-dependent) diabetes. Diabetologia 1988; 31: 162-167.
28. Thrainsdottir S, Malik RA, Dahlin LB, et al. Endoneurial capillary abnormalities presage deterioration of glucose tolerance and accompany peripheral neuropathy in man. Diabetes 2003; 52: 2615-2622.
29. Malik RA, Tesfaye S, Newrick PG, et al. Sural nerve pathology in diabetic patients with minimal but progressive neuro-pathy. Diabetologia 2005; 48: 578-585.
30. Yagihashi S. The pathogenesis of diabetic neuropathy. Diabetes Metab Res Rev 1995; 11: 193-225.
31. McCarthy BG, Hsieh ST, Stocks A, et al. Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology 1995; 45: 1848-1855.
32. Kennedy WR, Wendelschafer-Crabb G, Johnson T. Quantitation of epidermal nerves in diabetic neuropathy. Neurology 1996; 47: 1042-1048.
33. Polydefkis M, Hauer P, Sheth S, et al. The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain 2004; 127: 1606-1615.
34. Shun CT, Chang YC, Wu HP, et al. Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments. Brain 2004; 127: 1593-1605.
35. Smith AG, Ramachandran P, Tripp S, et al. Epidermal nerve innervations in impaired glucose tolerance and diabetes-associated neuropathy. Neurology 2001; 57: 1701-1704.
36. Sumner CJ, Sheth S, Griffin JW, et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003; 60: 108-111.
37. Malik RA, Kallinikos P, Abbott CA, et al. Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia 2003; 46: 683-638.
38. Hossain P, Sachdev A, Malik RA. Early detection of diabetic peripheral neuropathy with corneal confocal microscopy. Lancet 2005; 366: 1340-1343.
39. Quattrini C, Tavakoli M, Jeziorska M, et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes 2007; 56: 2148-2154.
40. Mehra S, Tavakoli M, Kallinikos PA, et al. Corneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 diabetes. Diabetes Care 2007; 30: 2608-2612.
41. Christianson JA, Riekhof JT, Wright DE. Restorative effects of neurotrophin treatment on diabetes-induced cutaneous axon loss in mice. Exp Neurol 2003; 179: 188-199.
42. Kennedy JM, Zochodne DW. Experimental diabetic neuropathy with spontaneous recovery: is there irreparable damage? Diabetes 2005; 54: 830-837.
43. Chattopadhyay M, Mata M, Goss J, et al. Prolonged preservation of nerve function in diabetic neuropathy in mice by herpes simplex virus-mediated gene transfer. Diabetologia 2007; 50: 1550-1558.
44. Leonelli E, Bianchi R, Cavaletti G, et al. Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: a multimodal analysis. Neuroscience 2007; 144: 1293-1304.
45. Stevens MJ, Zhang W, Li F, et al. C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats. Am J Physiol Endocrinol Metab 2004; 287: E497-E505.
46. Kuzumoto Y, Kusunoki S, Kato N, et al. Effect of the aldose reductase inhibitor fidarestat on experimental diabetic neuropathy in the rat. Diabetologia 2006; 49: 3085-3093.
47. Sugimoto K, Yagihashi S. Effects of aminoguanidine on structural alterations of microvessels in peripheral nerve of streptozotocin diabetic rats. Microvasc Res 1997; 53: 105-112.
48. Uehara K, Sugimoto K, Wada R, et al. Effects of cilostazol on the peripheral nerve function and structure in STZ-induced diabetic rats. J Diabetes Complications 1997; 11: 194-202.
49. Walker D, Carrington A, Cannan SA, et al. Structural abnormalities do not explain the early functional abnormalities in the peripheral nerves of the streptozotocin diabetic rat. J Anat 1999; 195: 419-427.
50. Goto Y, Hotta N, Shigeta Y, et al. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomed Pharmacother 1995; 49: 269-277.
51. Hotta N, Akanuma Y, Kawamori R, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 2006; 29: 1538-1544.
52. Hotta N, Kawamori R, Atsumi Y, et al. Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat. Diabet Med 2008; 25: 818-825.
53. Pfeifer MA, Schumer MP, Gelber DA. Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes 1997; 46(Suppl 2): S82-S89.
54. Ryan GJ. New pharmacologic approaches to treating diabetic retinopathy. Am J Health Syst Pharm 2007; 17(Suppl 12): S15-S21.
55. Gabbay KH. Hyperglycemia, polyol metabolism, and complications of diabetes mellitus. Annu Rev Med 1975; 26: 521-536.
56. Kinoshita JH. A thirty year journey in the polyol pathway. Exp Eye Res 1990; 50: 567-573.
57. Jakobsen J, Sidenius P. Nerve morphology in experimental diabetes. Clin Physiol 1985; 5(Suppl 5): 9-13.
58. Greene DA, Lattimer SA, Sima AA. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987; 316: 599-606.
59. Greene DA, Sima AA, Stevens MJ, et al. Complications: neuropathy, pathogenetic considerations. Diabetes Care 1992; 15: 1902-1925.
60. Dyck PJ, Sherman WR, Hallcher LM, et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980; 8: 590-596.
61. Dyck PJ, Zimmerman BR, Vilen TH, et al. Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. N Engl J Med 1988; 319: 542-548.
62. Drel VR, Mashtalir N, Ilnytska O, et al. The leptin-deficient (ob/ob) mouse: a new animal model of peripheral neuro-pathy of type 2 diabetes and obesity. Diabetes 2006; 55: 3335-3343.
63. Obrosova IG, Ilnytska O, Lyzogubov VV, et al. High-fat diet induced neuropathy of pre-diabetes and obesity: effects of "healthy" diet and aldose reductase inhibition. Diabetes 2007; 56: 2598-2608.
64. Yagihashi S, Yamagishi S, Wada R, et al. Galactosemic neuropathy in transgenic mice for human aldose reductase. Diabetes 1996; 45: 56-59.
65. Yagihashi S, Yamagishi SI, Wada R, et al. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain 2001; 124: 2448-2458.
66. Uehara K, Yamagishi S, Otsuki S, et al. Effects of polyol pathway hyperactivity on protein kinase C activity, nociceptive peptide expression, and neuronal structure in dorsal root ganglia in diabetic mice. Diabetes 2004; 53: 3239-3247.
67. Ho EC, Lam KS, Chen YS, et al. Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage. Diabetes 2006; 55: 1946-1953.
68. Yagihashi S, Yamagishi SI, Mizukami H, et al. Escape phenomenon from polyol pathway to other metabolic cascades may underlie nerve conduction delay in severely hyperglycemic AR-deficient mice. 68th American Diabetes Association, San Francisco, USA, June 6-10, 2008
69. Hwang YC, Shaw S, Kaneko M, et al. Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury. FASEB J 2005; 19: 795-797.
70. Iwata K, Matsuno K, Nishinaka T, et al. Aldose reductase inhibitors improve myocardial reperfusion injury in mice by a dual mechanism. J Pharmacol Sci 2006; 102: 37-46.
71. Cheung AK, Lo AC, So KF, et al. Gene deletion and pharmacological inhibition of aldose reductase protect against retinal ischemic injury. Exp Eye Res 2007; 85: 608-616.
72. Yeung CM, Lo AC, Cheung AK, et al. More severe type 2 diabetes-associated ischemic stroke injury is alleviated in aldose reductase-deficient mice. J Neurosci Res 2010; 88: 2026-2034.
73. Agardh CD, Agardh E, Obrosova IG, et al. The aldose reductase inhibitor fidarestat suppresses ischemia-reperfusion-induced inflammatory response in rat retina. Pharmacology 2009; 84: 257-263.
74. Yagihashi S, Mizukami H, Ogasawara S, et al. The role of the polyol pathway in acute kidney injury caused by hindlimb ischaemia in mice. J Pathol 2010; 220: 530-541.
75. Obrosova IG, Maksimchyk Y, Pacher P, et al. Evaluation of the aldose reductase inhibitor fidarestat on ischemia-reperfusion injury in rat retina. Int J Mol Med 2010; 26: 135-142.
76. Ramasamy R, Goldberg IJ. Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. Circ Res 2010; 106: 1449-1458.
77. Nukada H, Lynch CD, McMorran PD. Aggravated reperfusion injury in STZ-diabetic nerve. J Peripher Nerv Syst 2002; 7: 37-43.
78. Baba M, Nukada H, McMorran D, et al. Prolonged ischemic conduction failure after reperfusion in diabetic nerve. Muscle Nerve 2006; 33: 350-355.
79. Thornalley PJ. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol 2002; 50: 37-57.
80. Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des 2008; 14: 953-961.
81. Sugimoto K, Nishizawa Y, Horiuchi S, et al. Localization in human diabetic peripheral nerve of N(epsilon)-carboxymethyllysine-protein adducts, an advanced glycation endproduct. Diabetologia 1997; 40: 1380-1387.
82. Sekido H, Suzuki T, Jomori T, et al. Reduced cell replication and induction of apoptosis by advanced glycation end products in rat Schwann cells. Biochem Biophys Res Commun 2004; 320: 241-248.
83. Ryle C, Leow CK, Donaghy M. Nonenzymatic glycation of peripheral and central nervous system proteins in experimental diabetes mellitus. Muscle Nerve 1997; 20: 577-584.
84. Duran-Jimenez B, Dobler D, Moffatt S, et al. Advanced glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes. Diabetes 2009; 58: 2893-2903.
85. Wada R, Yagihashi S. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann N Y Acad Sci 2005; 1043: 598-604.
86. Haslbeck KM, Schleicher E, Bierhaus A, et al. The AGE/RAGE/NF-(kappa)B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). Exp Clin Endocrinol Diabetes 2005; 113: 288-291.
87. Vincent AM, Perrone L, Sullivan KA, et al. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology 2007; 148: 548-558.
88. Bierhaus A, Haslbeck KM, Humpert PM, et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 2004; 114: 1741-1751.
89. Toth C, Rong LL, Yang C, et al. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes 2008; 57: 1002-1017.
90. Kihara M, Schmelzer JD, Poduslo JF, et al. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA 1991; 88: 6107-6111.
91. Yagihashi S, Kamijo M, Baba M, et al. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 1992; 41: 47-52.
92. Wada R, Nishizawa Y, Yagihashi N, et al. Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur J Clin Invest 2001; 31: 513-520.
93. Cameron NE, Gibson TM, Nangle MR, et al. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. Ann N Y Acad Sci 2005; 1043: 784-792.
94. Nishizawa Y, Wada R, Baba M, et al. Neuropathy induced by exogenously administered advanced glycation end-products. J Diabetes Invest 2010; 1: 40-49.
95. Toth C, Martinez J, Zochodne DW. RAGE, diabetes, and the nervous system. Curr Mol Med 2007; 7: 766-776.
96. Lukic IK, Humpert PM, Nawroth PP, et al. The RAGE pathway: activation and perpetuation in the pathogenesis of diabetic neuropathy. Ann N Y Acad Sci 2008; 1126: 76-80.
97. Haupt E, Ledermann H, Köpcke W. Benfotiamine in the treatment of diabetic polyneuropathy - a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther 2005; 43: 71-77.
98. Greene DA, Stevens MJ, Obrosova I, et al. Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. Eur J Pharmacol 1999; 375: 217-223.
99. Pop-Busui R, Sima A, Stevens M. Diabetic neuropathy and oxidative stress. Diabetes Metab Res Rev 2006; 22: 257-273.
100. Obrosova IG. Diabetes and the peripheral nerve. Biochim Biophys Acta 2009; 1792: 931-940.
101. Cameron NE, Cotter MA. Potential therapeutic approaches to the treatment or prevention of diabetic neuropathy: evidence from experimental studies. Diabet Med 1993; 10: 593-605.
102. Cameron NE, Cotter MA, Maxfield EK. Anti-oxidant treatment prevents the development of peripheral nerve dysfunction in streptozotocin-diabetic rats. Diabetologia 1993; 36: 299-304.
103. Kishi Y, Schmelzer JD, Yao JK, et al. Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. Diabetes 1999; 48: 2045-2051.
104. Stevens MJ, Obrosova I, Cao X, et al. Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 2000; 49: 1006-1015.
105. Leinninger GM, Edwards JL, Lipshaw MJ, et al. Mechanisms of disease: mitochondria as new therapeutic targets in diabetic neuropathy. Nat Clin Pract Neurol 2006; 2: 620-628.
106. Edwards JL, Quattrini A, Lentz SI, et al. Diabetes regulates mitochondrial biogenesis and fission in mouse neurons. Diabetologia 2010; 53: 160-169.
107. Vincent AM, McLean LL, Backus C, et al. Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. FASEB J 2005; 19: 638-640.
108. Zherebitskaya E, Akude E, Smith DR, et al. Development of selective axonopathy in adult sensory neurons isolated from diabetic rats: role of glucose-induced oxidative stress. Diabetes 2009; 58: 1356-1364.
109. Huang TJ, Price SA, Chilton L, et al. Diabetes. Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia. Diabetes 2003; 52: 2129-2136.
110. Drel VR, Pacher P, Stevens MJ, et al. Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells. Free Radic Biol Med 2006; 40: 1454-1465.
111. Obrosova IG, Pacher P, Szabó C, et al. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes 2005; 54: 234-242.
112. Obrosova IG, Van Huysen C, Fathallah L, et al. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 2002; 16: 123-125.
113. Kamiya H, Zhang W, Sima AA. Degeneration of the Golgi and neuronal loss in dorsal root ganglia in diabetic BioBreeding/Worcester rats. Diabetologia 2006; 49: 2763-2774.
114. Obrosova IG, Drel VR, Oltman CL, et al. Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats. Am J Physiol Endocrinol Metab 2007; 293: E1645-E1655.
115. Obrosova IG, Li F, Abatan OI, et al. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 2004; 53: 711-720.
116. Towns R, Pietropaolo M, Wiley JW. Stimulation of autophagy by autoantibody-mediated activation of death receptor cascades. Autophagy 2008; 4: 715-716.
117. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995; 38: 1425-1433.
118. Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular complications. Diabet Med 2001; 18: 945-959.
119. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010; 106: 1319-1331.
120. Kasajima H, Yamagishi S, Sugai S, et al. Enhanced in situ expression of aldose reductase in peripheral nerve and renal glomeruli in diabetic patients. Virchows Arch 2001; 439: 46-54.
121. Nakamura J, Kato K, Hamada Y, et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999; 48: 2090-2095.
122. Yamagishi S, Uehara K, Otsuki S, et al. Differential influence of increased polyol pathway on protein kinase C expressions between endoneurial and epineurial tissues in diabetic mice. J Neurochem 2003; 87: 497-507.
123. Kamiya H, Nakamura J, Hamada Y, et al. Polyol pathway and protein kinase C activity of rat Schwannoma cells. Diabetes Metab Res Rev 2003; 19: 131-139.
124. Cameron NE, Cotter MA. Effects of protein kinase Cbeta inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism. Diabetes Metab Res Rev 2002; 18: 315-323.
125. Sasase T, Yamada H, Sakoda K, et al. Novel protein kinase C-beta isoform selective inhibitor JTT-010 ameliorates both hyper- and hypoalgesia in streptozotocin- induced diabetic rats. Diabetes Obes Metab 2005; 7: 586-594.
126. Casellini CM, Barlow PM, Rice AL, et al. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care 2007; 30: 896-902.
127. Shangguan Y, Hall KE, Neubig RR, et al. Diabetic neuropathy: inhibitory G protein dysfunction involves PKC-dependent phosphorylation of Goalpha. J Neurochem 2003; 86: 1006-1014.
128. Sakaue Y, Sanada M, Sasaki T, et al. Amelioration of retarded neurite outgrowth of dorsal root ganglion neurons by overexpression of PKCdelta in diabetic rats. Neuroreport 2003; 14: 431-436.
129. Younger DS, Rosoklija G, Hays AP, et al. Diabetic peripheral neuropathy: a clinicopathologic and immunohistochemical analysis of sural nerve biopsies. Muscle Nerve 1996; 19: 722-727.
130. Satoh J, Yagihashi S, Toyota T. The possible role of tumor necrosis factor-alpha in diabetic polyneuropathy. Exp Diabesity Res 2003; 4: 65-71.
131. Conti G, Scarpini E, Baron P, et al. Macrophage infiltration and death in the nerve during the early phases of experimental diabetic neuropathy: a process concomitant with endoneurial induction of IL-1beta and p75NTR. J Neurol Sci 2002; 195: 35-40.
132. Yagihashi S, Yamagishi S, Wada R. Pathology and pathogenetic mechanisms of diabetic neuropathy: correlation with clinical signs and symptoms. Diabetes Res Clin Pract 2007; 77(Suppl 1): S184-S189.
133. Sagara M, Satoh J, Wada R, et al. Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine. Diabetologia 1996; 39: 263-269.
134. Yamagishi S, Ogasawara S, Mizukami H, et al. Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-gamma-ligand, in insulin-deficient diabetic rats. J Neurochem 2008; 104: 491-499.
135. Pop-Busui R, Marinescu V, Van Huysen C, et al. Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration. Diabetes 2002; 51: 2619-2628.
136. Kellogg AP, Converso K, Wiggin T, et al. Effects of cyclooxygenase-2 gene inactivation on cardiac autonomic and left ventricular function in experimental diabetes. Am J Physiol Heart Circ Physiol 2009; 296: H453-H461.
137. Tomlinson DR. Mitogen-activated protein kinases as glucose transducers for diabetic complications. Diabetologia 1999; 42: 1271-1281.
138. Du Y, Tang J, Li G, et al. Effects of p38 MAPK inhibition on early stages of diabetic retinopathy and sensory nerve function. Invest Ophthalmol Vis Sci 2010; 51: 2158-2164.
139. Wang Y, Schmeichel AM, Iida H, et al. Enhanced inflam-matory response via activation of NF-kappaB in acute experimental diabetic neuropathy subjected to ischemia-reperfusion injury. J Neurol Sci 2006; 247: 47-52.
140. Kumar A, Sharma SS. NF-kappaB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem Biophys Res Commun 2010; 394: 360-365.
141. Ramos KM, Jiang Y, Svensson CI, et al. Pathogenesis of spinally mediated hyperalgesia in diabetes. Diabetes 2007; 56: 1569-1576.
142. Doupis J, Lyons TE, Wu S, et al. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab 2009; 94: 2157-2163.
143. Saini AK, Kumar HSA, Sharma SS. Preventive and curative effect of edaravone on nerve functions and oxidative stress in experimental diabetic neuropathy. Eur J Pharmacol 2007; 568: 164-172.
144. Tomlinson DR, Fernyhough P, Diemel LT. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors. Diabetes 1997; 46(Suppl 2): S43-S49.
145. Zochodne DW. Neurotrophins and other growth factors in diabetic neuropathy. Semin Neurol 1996; 16: 153-161.
146. Apfel SC. Neurotrophic factors in the therapy of diabetic neuropathy. Am J Med 1999; 107: 34S-42S.
147. Pittenger G, Vinik A. Nerve growth factor and diabetic neuropathy. Exp Diabesity Res 2003; 4: 271-285.
148. Hellweg R, Hartung HD. Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res 1990; 26: 258-267.
149. Anand P, Terenghi G, Warner G, et al. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med 1996; 2: 703-707.
150. Apfel SC, Arezzo JC, Brownlee M, et al. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res 1994; 634: 7-12.
151. Elias KA, Cronin MJ, Stewart TA, et al. Peripheral neuropathy in transgenic diabetic mice: restoration of C-fiber function with human recombinant nerve growth factor. Diabetes 1998; 47: 1637-1642.
152. Schmidt RE, Dorsey DA, Beaudet LN, et al. Effect of NGF and neurotrophin-3 treatment on experimental diabetic autonomic neuropathy. J Neuropathol Exp Neurol 2001; 60: 263-273.
153. Andreassen CS, Jakobsen J, Flyvbjerg A, et al. Expression of neurotrophic factors in diabetic muscle - relation to neuropathy and muscle strength. Brain 2009; 132: 2724-2733.
154. Huang TJ, Sayers NM, Verkhratsky A, et al. Neurotrophin-3 prevents mitochondrial dysfunction in sensory neurons of streptozotocin-diabetic rats. Exp Neurol 2005; 194: 279-283.
155. Middlemas A, Delcroix JD, Sayers NM, et al. Enhanced activation of axonally transported stress-activated protein kinases in peripheral nerve in diabetic neuropathy is prevented by neurotrophin-3. Brain 2003; 126: 1671-1682.
156. Christianson JA, Ryals JM, Johnson MS, et al. Neurotrophic modulation of myelinated cutaneous innervation and mechanical sensory loss in diabetic mice. Neuroscience 2007; 145: 303-313.
157. Apfel SC, Kessler JA, Adornato BT, et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 1998; 51: 695-702.
158. Price SA, Dent C, Duran-Jimenez B, et al. Gene transfer of an engineered transcription factor promoting expression of VEGF-A protects against experimental diabetic neuropathy. Diabetes 2006; 55: 1847-1854.
159. Murakami T, Arai M, Sunada Y, et al. VEGF 164 gene transfer by electroporation improves diabetic sensory neuropathy in mice. J Gene Med 2006; 8: 773-781.
160. Kim H, Park JS, Choi YJ, et al. Bone marrow mononuclear cells have neurovascular tropism and improve diabetic neuropathy. Stem Cells 2009; 27: 1686-1696.
161. Jeong JO, Kim MO, Kim H, et al. Dual angiogenic and neurotrophic effects of bone marrow-derived endothelial progenitor cells on diabetic neuropathy. Circulation 2009; 119: 699-708.
162. Terashima T, Kojima H, Fujimiya M, et al. The fusion of bone-marrow-derived proinsulin-expressing cells with nerve cells underlies diabetic neuropathy. Proc Natl Acad Sci USA 2005; 102: 12525-12530.
163. Busik JV, Tikhonenko M, Bhatwadekar A, et al. Diabetic neuropathy is associated with bone marrow neuropathy and a depressed peripheral clock. J Exp Med 2010; 206: 2897-2906.
164. Imai J, Katagiri H, Yamada T, et al. Regulation of pancreatic beta cell mass by neuronal signals from the liver. Science 2008; 322: 1250-1254.